RDIF seeks Indian regulatory nod for Sputnik M registration
New Delhi: The Russian Direct Investment Fund (RDIF) said on Monday that it has provided documents to India's regulator for the registration of Sputnik M, the vaccine for adolescents aged 12-17.
"RDIF has provided India's regulator with documents for registration of Sputnik M - the vaccine for adolescents aged 12-17. Russia's Health Ministry registered Sputnik M on November 24. It has become a new member of the Sputnik vaccines family and is offered to international markets, joining Sputnik V and Sputnik Light," the RDIF said in a statement.
"Subject to the positive decision of India's authorities, Sputnik M could become the first registered vaccine for adolescents in the country and make an important contribution in protecting the younger population," the statement added.
The Sputnik V vaccine is already being used in India after it received emergency use authorisation in April 2021. Sputnik V is the first foreign-made vaccine to be used in India.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.